Shareholders of Norwegian contrast developer Hafslund Nycomedhave approved a plan to demerge the company's energy businessfrom its pharmaceutical unit. Under the plan, the Oslo company'spharmaceutical business will be known as Nycomed ASA, while
Shareholders of Norwegian contrast developer Hafslund Nycomedhave approved a plan to demerge the company's energy businessfrom its pharmaceutical unit. Under the plan, the Oslo company'spharmaceutical business will be known as Nycomed ASA, while theenergy unit will be called Hafslund ASA. Nycomed shares will betraded on the Oslo, London, and Copenhagen exchanges, while NycomedAmerican Depository Receipts will be listed on the New York StockExchange under the symbol "NYD."
Seven Takeaways from New Analysis of Malpractice Cases Involving Interventional Radiologists
September 27th 2023Thirty-five percent of the interventional radiology malpractice cases involved vascular procedures and 26 percent of overall malpractice cases that went to trial resulted in plaintiff judgments with the average award being over $2 million.
2 Clarke Drive
Cranbury, NJ 08512